Belluscura
Belluscura PLC is a UK-listed medical device company (formerly AIM: BELL) that develops the X-PLOR® portable oxygen concentrator for oxygen-therapy patients, distributing through US Durable Medical Equipment (DME) providers; following its US subsidiary's December 2025 Chapter 7 filing the parent entered administration and departed AIM.
- Company typePublic
- Founded2015
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Belluscura does
Belluscura PLC is a UK-domiciled medical device company that develops, markets, and distributes the X-PLOR® portable oxygen concentrator (POC), a lightweight, rechargeable, compact supplemental oxygen device intended as a replacement for heavy oxygen tanks. The X-PLOR platform is built around the company's proprietary ModulAir® gas separation technology and its Airgonomical™ industrial design philosophy, delivering pulse-dose oxygen across settings 1 through 6+ from a single portable unit. Supporting offerings include a line of oxygen accessories (batteries, chargers, bags) and a companion mobile app that provides usage guidance and community engagement for X-PLOR owners.
The company distributes its devices primarily through Durable Medical Equipment (DME) providers in the US healthcare market, accessed via a dedicated B2B portal at belluscurahealth.com, with a direct-to-consumer front-end used to capture leads, collect consent-based phone and SMS follow-up, and route fulfillment to the DME channel. End customers are patients requiring supplemental oxygen across a wide flow-setting range, supported by caregivers, family members, and prescribing clinicians. Pricing is quote-based rather than list-published, consistent with DME-channel medical device sales.
Belluscura was founded in 2015, listed on London's AIM market under the ticker BELL, and operated a US subsidiary headquartered in Plano, Texas. As of December 2025, the US subsidiary has filed for Chapter 7 bankruptcy following exhaustion of working capital (approximately $1M remaining cash against $790,000 of debt), an administrator has been appointed at the UK parent level, and the company has voluntarily departed AIM. Leadership comprises Robert Rauker (CEO) and Simon Neicheril (CFO).
Belluscura firmographics
Firmographics- Name
- Belluscura
- Legal name
- Belluscura
- Website
- https://belluscura.com
- Company type
- Public
- Founded year
- 2015
- Headcount range
- 11–50 employees
- Short description
- Belluscura PLC is a UK-listed medical device company (formerly AIM: BELL) that develops the X-PLOR® portable oxygen concentrator for oxygen-therapy patients, distributing through US Durable Medical Equipment (DME) providers; following its US subsidiary's December 2025 Chapter 7 filing the parent entered administration and departed AIM.
- Ownership category
- akta.pro rank
Belluscura industry classification
Industry- Product category
- Portable Oxygen Concentrators
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC) (HLAHAGAD)
Keywords
Where Belluscura is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Belluscura business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- X-PLOR Portable Oxygen Concentrator Hardware Sales: Primary revenue from one-time unit sales of the X-PLOR portable oxygen concentrator, distributed via DME providers and direct-to-consumer channels; sources include DME portal accounts indicating B2B hardware fulfillment.
- Oxygen Concentrator Accessories: Recurring/aftermarket revenue from accessories (battery, chargers, bags, etc.) sold via the website's Accessories product category to support and maintain X-PLOR devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for X-PLOR device and accessories, handled via DME providers and inside sales. |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels10 records
Belluscura product offering
Product offeringCore offering
Belluscura designs, manufactures and distributes the X-PLOR® portable oxygen concentrator — a lightweight, rechargeable POC built on proprietary ModulAir® gas separation and Airgonomical™ design — sold primarily through DME providers, supported by a line of oxygen therapy accessories and a companion mobile app. The device targets patients requiring portable supplemental oxygen at flow settings from 1 through 6+, positioning as a replacement for heavy oxygen tanks.
Product overview
Belluscura offers a focused single-therapeutic-area portfolio centered on its core portable oxygen concentrator, the X-PLOR®, supplemented by a dedicated line of Oxygen Accessories (browseable from the navigation menu at /product-category/accessories/) and a Belluscura mobile App (linked under Resources at /our-app/) that supports device users. Together the X-PLOR device, the accessories line, and the companion app form a coherent supplemental-oxygen therapy offering targeting patients, loved ones, and clinicians/DME providers, with distribution handled through a dedicated DME Provider portal and account login.
Differentiator
Problem solved
Functional benefit
Products and services
- X-PLOR® Portable Oxygen Concentrator Lightweight, compact, rechargeable portable oxygen concentrator built on proprietary ModulAir® gas separation and Airgonomical™ design, delivering high oxygen output across multiple pulse-dose settings (1–6+) as a portable alternative to heavy oxygen tanks and stationary concentrators for supplemental oxygen therapy patients.
- Oxygen Accessories Companion accessories (such as batteries, chargers, and bags) that support and maintain the X-PLOR portable oxygen concentrator, sold via the Belluscura Health website's accessories category.
- Belluscura App Companion mobile application for X-PLOR owners providing app-based support, device usage guidance, and community engagement for oxygen therapy users.
Quantifiable outcome
- Approximately $1 million remaining cash against $790,000 of debt at the time of AIM departure, signaling exhaustion of working capital and triggering Chapter 7 administration of the US subsidiary in December 2025.
- +1 more outcomes
Companies that use Belluscura
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Belluscura technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Belluscura partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights2 records
Belluscura competitors and assessment
Company assessmentBroad incumbents
- Philips Respironics: Large incumbent in respiratory care with the SimplyGo and EverFlo portable and stationary oxygen concentrator lines, distributed through the same DME channel that Belluscura targets; broader portfolio but the most direct large-company competition in POCs.
- ResMed: Global respiratory and sleep-apnea device leader that has expanded into portable oxygen; competes for the same DME and clinician relationships that drive X-PLOR adoption.
Emerging players
- Precision Medical: Manufacturer of portable oxygen concentrators and respiratory accessories targeting homecare and DME providers, comparable in product scope and channel to Belluscura.
- 3B Medical: Sleep and respiratory device company that has expanded into portable oxygen offerings (e.g., Aer), overlapping with Belluscura in DME and homecare distribution.
- O2 Concepts: Smaller US-based portable oxygen concentrator manufacturer (Oxlife Liberty, Oxlife Independence) competing in the same DME channel with a focus on high-flow portable devices.
Regional players
- GCE Group: European-headquartered manufacturer of medical gas and oxygen therapy equipment including portable concentrators, comparable technology and overlapping home oxygen use case, but primarily a regional/international peer to Belluscura's US-focused operations.
Direct peers
- Invacare: Long-standing DME manufacturer with the XPO2 and other portable oxygen concentrators serving the same DME and patient population as Belluscura.
- Drive DeVilbiss Healthcare: Major DME manufacturer offering the iGo2 and other portable oxygen concentrators distributed through the same DME and homecare channels as Belluscura.
- Caire (Chart Industries): Manufacturer of portable and stationary oxygen concentrators (e.g., FreeStyle, eQuinox) sold via DME providers; directly comparable in product, channel, and patient population.
- Inogen: Pure-play US manufacturer of portable oxygen concentrators (e.g., Inogen One) sold through DME providers and direct to patients; directly comparable to Belluscura in product category, customer base, and DME-plus-DTC distribution model.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights4 records
Customer concentration
Belluscura social profiles
Digital presenceBelluscura financial estimates
Financial estimateRevenue estimate
Valuation estimate
Belluscura leadership team
Management profileNumber of profiles
Profiles2 records
Belluscura subsidiaries and ownership
Company hierarchySubsidiaries1 record
Belluscura funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Belluscura M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Belluscura
What does Belluscura do?
Belluscura designs, manufactures and distributes the X-PLOR® portable oxygen concentrator — a lightweight, rechargeable POC built on proprietary ModulAir® gas separation and Airgonomical™ design — sold primarily through DME providers, supported by a line of oxygen therapy accessories and a companion mobile app. The device targets patients requiring portable supplemental oxygen at flow settings from 1 through 6+, positioning as a replacement for heavy oxygen tanks.
Is Belluscura a public or private company?
Belluscura is a public company. It is classified as public.
When was Belluscura founded?
Belluscura was founded in 2015. It employs 11 to 50 people.
Where is Belluscura based?
Belluscura is headquartered in London, United Kingdom, in the Europe region.
How does Belluscura make money?
Two revenue lines are on record. X-PLOR Portable Oxygen Concentrator Hardware Sales are the primary driver. The others are oxygen Concentrator Accessories.
Who are Belluscura's main competitors?
Broad incumbents on record are Philips Respironics and ResMed. Emerging players are Precision Medical, 3B Medical and O2 Concepts. GCE Group is listed as a regional player. Direct peers are Invacare, Drive DeVilbiss Healthcare, Caire (Chart Industries) and Inogen.
Does Belluscura have an API?
No public API is recorded for Belluscura.
What industry is Belluscura in?
Belluscura's product category is Portable Oxygen Concentrators. Its primary akta.pro industry code is HLAHAGAD, Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC). Its NAICS code is 334510 and its SIC code is 3845.